............................
2015
2014
2013
Archive
............................
Portfolio News
............................
New Leaf News
............................
|
Synageva Biopharma Receives Orphan
Drug Designation for SBC-102 for Lysosomal Acid Lipase Deficiency
WALTHAM, Mass, July 7, 2010 -- Synageva BioPharma Corp., a
privately held biopharmaceutical company, announced that the U.S. Food
and Drug Administration (FDA) has granted orphan drug designation for
SBC-102, the Company’s enzyme replacement therapy in development to
treat Lysosomal Acid Lipase (LAL) Deficiency, also known as Wolman
Disease and Cholesteryl Ester Storage Disease (CESD), a condition for
which there is currently no approved treatment.
As a result of the orphan drug designation, Synageva BioPharma
will be eligible to receive a number of benefits, including access to
grant funding for clinical trials, tax credits, waiver of the FDA filing
and registration fees, and seven years of market exclusivity upon
approval. U.S. orphan drug designation is granted to a product that
treats a rare disease, a condition that affects fewer than 200,000
Americans.
About Synageva BioPharma Corp.
Synageva BioPharma Corp. is dedicated to discovering, developing
and commercializing therapies for patients with rare conditions and high
unmet medical need. The Company has developed a pipeline of novel
therapeutics for underserved populations and has assembled a team with a
proven record of bringing orphan therapies to patients. Synageva
BioPharma has the ability to use its proprietary protein expression
technology (SEP™), which due to its flexibility, scalability and
consistency of end product is uniquely suited for the development and
commercialization of personalized medicines for patients with rare
diseases. Further information regarding Synageva BioPharma Corp. is
available at www.synageva.com.
Company Contact
Chris Heberlig
Synageva BioPharma Corp.
Tel: (781) 890-1111
chris.heberlig @synageva.com
Media Contact
Michele Parisi
BioComm Network
Tel: (925) 429-1850
mparisi @biocommnetwork.com |